Review: Type 2 diabetes: how far have we come?

Abstract

The last 50 years has witnessed the recognition of type 2 diabetes as a complex heterogeneous disease that results from an interaction between environmental factors and genetic predispositions. As its pathophysiology has been unfolded by the advances in clinical science, so its prevalence has increased dramatically, and it is now one of the major personal and public health problems worldwide. Therapeutic approaches to address insulin resistance and beta-cell dysfunction have intensified and diversified during the last decade, driven by indisputable evidence that the treatment goals include both glycaemic control and attention to all vascular risk factors. Advances in basic and clinical research over the last fifty years have culminated in sufficient strategies and pharmacological agents to start to achieve these goals. Equally as important, they have laid the foundation for what promise to be remarkable future developments.

Keywords

treatment and prevention of type 2 diabetes insulin resistance insulin deficiency metabolic syndrome.

Get full access to this article

View all access options for this article.

References

Tuomilehto J. , Lindstrom J. , Eriksson JG et al. Finnish Diabetes Preventation Group. Preventation of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 ;344:1343-50.

Knowler WC , Barrett-Connor E. , Fowler SE et al. Diabetes Prevention Program Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

Buchanan TA , Xiang AH , Peters RK et al. Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803.

Chiasson JL , Josse RG , Gomis R. , Hanefeld M. , Karasik A. , Laasko M. , STOP-NIDDM Trial Research Group. Acarbose for the prevention of type 2 diabetes the STOP-NIDDM randomized trial. Lancet 2002;359:2072-7.

Xu G. , Stoffers DA , Habener JF , Bonner-Weir S. Exenden-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta cell mass and improved glucose tolerance in diabetic rats . Diabetes 1999;48:2270-6.

Yalow RS , Berson SA Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157-75.

DeFronzo RA , Tobin JD , Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance . Am J Physiol 1979;237: E214-223.

Steiner DF , Cunningham D. , Spigelman L. , Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967;157:697-700.

Bell GI , Pictet RL , Rutter WJ , Cordell B. , Tischer E. , Goodman HM Sequence of the human insulin gene. Nature 1980;284:26-32.

10.

Chan SJ , Weiss J. , Konrad M. et al. Biosynthesis and periplasmic segregation of human proinsulin in Escherichia coli. Proc Nat Acad Sci USA 1981;78:5401-08.

11.

Aguilar-Bryan L. , Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999;20:101-35.

12.

Miki T. , Nagashima K. , Seino S. The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta cells. J Mol Endocrinol 1999 ;22:113-23.

13.

Yalow RS , Black H. , Villazon M. , Berson SA Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes 1960;9:356-62.

14.

Himsworth HP Diabetes mellitus. A differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936 ;1:127-30.

15.

Sicree RA , Zimmet PZ , King HO , Coventry JS Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 years. Diabetes 1987;36:179-86.

16.

Haffner SM , Stern MP , Mitchell BD , Hazuda HP , Patterson JK Incidence of type 2 diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity and body-fat distribution. Diabetes 1990;39:283-8.

17.

Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19:477-90.

18.

Gerich JE The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.

19.

Pimenta W. , Korytkowski M. , Mitrakou A. et al.: Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM, Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995;273:1855-61.

20.

Weyer C. , Bogardus C. , Mott DM , Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.

21.

Vague J. The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease . Am J Clin Nutr 1956;4:20-34.

22.

Reaven GM Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.

23.

Stern M. The Insulin Resistance Syndrome. In: Alberti KGMM , Zimmet P , DeFronzo RA , Keen H , eds. International Textbook of Diabetes Mellitus, Second Edition. Chichester: John Wiley & Sons Ltd, 1997:255-83.

24.

Lebovitz HE Clinician's Manual on Insulin Resistance. London: Science Press Ltd.; 2002.

25.

Ford ES , Giles WH , Dietz WH Prevalence of the Metabolic Syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002;287:356-9.

26.

Isomaa B. , Almgren P. , Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-9.

27.

Hanley AJ , Williams K. , Stern MP , Haffner SM Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-84.

28.

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

29.

UK Prospective Diabetes Study Group : Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

30.

Stratton IM , Adler AI , Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

31.

Damsbo P. , Marbury TC , Clauson P. , Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22:789-94.

32.

Horton ES , Foley J. , Clinkingbeard C. , Foley J. , Mallow S. , Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5.

33.

Hu S. , Wang S. , Fanelli B. , Bell PA et al.: Pancreatic beta-cell KATP channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide . J Pharmacol Exp Ther 2000;293:444-52.

34.

Zander M. , Madsbad S. , Madsen JL , Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study . Lancet 2002;359:824-30.

35.

Lebovitz HE Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001;30:909-33.

36.

Inzucchi SE Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002;287:360-72.

37.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 1998;317:703-13.

38.

Hansson L. , Zanchetti A. , Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.

39.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.

40.

Goldberg RB , Mellies MJ , Sacks FM et al. for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998;98:2513-19.

41.

Willson TM , Lambert MH , Kliewer SA Peroxisome proliferator-activated receptor and metabolic disease. Annu Rev Biochem 2001;70:341-67.

42.

Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106:459-65.

43.

Roden M. , Petersen KF , Shulman GI Nuclear magnetic resonance studies of hepatic glucose metabolism in humans . Recent Prog Horm Res 2001; 56:219-37.